ViroPharma Inc. (NASDAQ:VPHM) recently provided sales and expense guidance for 2012. The company expects net product sales in the range of $600 – $660 million. Further, ViroPharma forecasts US Cinryze sales to come in at $310 – $330 million, with Vancocin sales expected to range from $260 – $310 million.
Additionally, the company anticipates research and development (R&D) and selling, general and administrative (SG&A) expenses to be in the $230 – $260 million range.
We note that the 2012 … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards